{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:40:16Z","timestamp":1792460416474,"version":"4.5.0"},"reference-count":218,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ctrv.2021.102259","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T01:17:21Z","timestamp":1625966241000},"page":"102259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS \u2013 GROUP). Part I"],"prefix":"10.1016","volume":"99","author":[{"given":"Javier","family":"Mart\u00ednez-Trufero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Cruz Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Carmen","family":"G\u00f3mez-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bernabeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Javier","family":"Flor\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Lavernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sebio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Garc\u00eda del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Nieves","family":"Hern\u00e1ndez-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Asencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Valverde Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martin-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctrv.2021.102259_b0005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumors: results of RARECAREnet-a population-based study [published correction appears in Lancet Oncol. 2017 Aug;18(8):e433]","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0010","unstructured":"Fletcher C DM, Baldini EH, Blay JY, Gronchi A, et al. WHO Classification of Tumors of Soft Tissue and Bone. 5th ed. WHO 2020;IARC WHO Classification of Tumors, No 3. ISBN-9789283245025."},{"key":"10.1016\/j.ctrv.2021.102259_b0015","article-title":"Soft tissue and visceral sarcomas. ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow up","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-015-2809-5","article-title":"Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)","volume":"77","author":"Garcia del Muro","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0025","doi-asserted-by":"crossref","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"De Pinieux","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2021.102259_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Centers for Disease C, Prevention. Infectious Diseases Society of A. American Society of B, Marrow T Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anndiagpath.2010.07.012","article-title":"Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007","volume":"15","author":"Albores-Saavedra","year":"2011","journal-title":"Ann Diagn Pathol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102259_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fonc.2018.00046","article-title":"Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor","volume":"2","author":"Fujisawa","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0050","series-title":"Intermediate malignant and malignant tumors of soft tissue featuring a spindle cell morphology. Soft tissue sarcomas. A pattern-based approach to diagnosis","first-page":"578","author":"Dei Tos","year":"2019"},{"key":"10.1016\/j.ctrv.2021.102259_b0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.critrevonc.2019.04.010","article-title":"Targeting, angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease","volume":"138","author":"Weidema","year":"2019","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0060","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.currproblcancer.2015.07.007","article-title":"Cutaneous angiosarcoma","volume":"39","author":"Dossett","year":"2015","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0070","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.suronc.2018.08.008","article-title":"Evolving radiation therapy techniques for scalp angiosarcoma","volume":"27","author":"Ko","year":"2018","journal-title":"Surg Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0075","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/cncr.26543","article-title":"The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma","volume":"118","author":"Riad","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102259_b0080","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3390\/cancers12082251","article-title":"Neoadjuvant Systemic Treatment of Primary Angiosarcoma","volume":"12","author":"Heinhuis","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102259_b0085","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/annonc\/mdm381","article-title":"Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases","volume":"18","author":"Fayette","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000787","article-title":"Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study","volume":"5","author":"Constantinidou","year":"2020","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.ctrv.2021.102259_b0095","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0100","doi-asserted-by":"crossref","DOI":"10.1177\/2036361318771771","article-title":"A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma","volume":"10","author":"Bui","year":"2018","journal-title":"Rare Tumors"},{"issue":"25","key":"10.1016\/j.ctrv.2021.102259_b0105","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial","volume":"33","author":"Ray-Coquard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0110","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/bjc.2017.187","article-title":"Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma","volume":"117","author":"Vincenzi","year":"2017","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.ctrv.2021.102259_b0115","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2021.102259_b0120","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1200\/JCO.2008.20.9890","article-title":"Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas","volume":"27","author":"George","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0135","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1186\/s12885-020-07199-0","article-title":"Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma","volume":"20","author":"Tian","year":"2020","journal-title":"BMC Cancer"},{"issue":"3\u20134","key":"10.1016\/j.ctrv.2021.102259_b0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.18632\/oncoscience.413","article-title":"Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma","volume":"5","author":"Amaya","year":"2018","journal-title":"Oncoscience"},{"key":"10.1016\/j.ctrv.2021.102259_b0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","article-title":"Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study","volume":"6","author":"Pasquier","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution [published correction appears in J Immunother Cancer. 2019 Nov 6;7(1):285]","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0155","first-page":"259","article-title":"Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor","volume":"8","author":"Sardaro","year":"2014","journal-title":"Oncol Rev"},{"key":"10.1016\/j.ctrv.2021.102259_b0160","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/gcc.20886","article-title":"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites","volume":"50","author":"Errani","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002409","article-title":"Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma","volume":"3","author":"Tanas","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2021.102259_b0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.path.2018.10.002","article-title":"The Molecular Diagnostics of Vascular Neoplasms","volume":"12","author":"Habeeb","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.ctrv.2021.102259_b0175","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/gcc.22073","article-title":"Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma","volume":"52","author":"Antonescu","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2021.102259_b0180","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1038\/modpathol.2013.176","article-title":"Malignant vascular tumors\u2014an update","volume":"27","author":"Antonescu","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/PAS.0000000000000511","article-title":"Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics","volume":"40","author":"Doyle","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11864-018-0536-y","article-title":"Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment","volume":"19","author":"Rosenberg","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.hbpd.2019.11.006","article-title":"Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2014","volume":"19","author":"Noh","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0200","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jso.24979","article-title":"Primary liver sarcomas in the modern era: Resection or transplantation?","volume":"117","author":"Konstantinidis","year":"2018","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0205","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/TP.0000000000001603","article-title":"Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry","volume":"101","author":"Lai","year":"2017","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102259_b0210","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.21873\/anticanres.13675","article-title":"The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma","volume":"39","author":"Tong","year":"2019","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00000478-198201000-00006","article-title":"Hemangioendothelial sarcoma of bone","volume":"6","author":"Wold","year":"1982","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0220","first-page":"4597","article-title":"Radiotherapy as an effective primary treatment for epithelioid haemangioendothelioma of the cervical spine","volume":"32","author":"Yim","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2021.102259_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.3807","article-title":"Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature","author":"Frezza","year":"2021","journal-title":"Cancer Med"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102259_b0230","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/cncr.28109","article-title":"Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF\/GETO)","volume":"119","author":"Chevreau","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0235","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.33247","article-title":"Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0240","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.11503","article-title":"P10015\/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE)","volume":"39","author":"Schuetze","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0245","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.canep.2014.09.009","article-title":"Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project","volume":"38","author":"Stiller","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ctrv.2021.102259_b0250","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2013.51.6757","article-title":"Prospective stage-stratified approach to AIDS-related Kaposi\u2019s sarcoma","volume":"32","author":"Bower","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0255","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ajcp\/aqx072","article-title":"Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions","volume":"148","author":"Hoda","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0260","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0360-3016(93)90523-X","article-title":"A randomized prospective trial of radiation therapy for AIDS-associated Kaposi\u2019s sarcoma","volume":"27","author":"Stelzer","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102259_b0265","first-page":"1136","article-title":"Radiotherapy in the management of Kaposi\u2019s sarcoma: comparison of 8 Gy versus 6 Gy","volume":"98","author":"Yildiz","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.ctrv.2021.102259_b0270","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2008.03.009","article-title":"Hypofractionated radiation therapy in the treatment of epidemic Kaposi sarcoma\u2014a prospective randomized trial","volume":"88","author":"Singh","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0275","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/archderm.138.4.542","article-title":"Topical 0.1% alitretinoin gel for classic Kaposi sarcoma","volume":"138","author":"Morganroth","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2021.102259_b0280","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2133.2009.09601.x","article-title":"Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients","volume":"162","author":"Brambilla","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2021.102259_b0285","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/DSS.0000000000000973","article-title":"Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study","volume":"43","author":"Ozdemir","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ctrv.2021.102259_b0290","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2133.1993.tb00490.x","article-title":"The therapeutic effect of intralesional interferon in classical Kaposi\u2019s sarcoma","volume":"129","author":"Trattner","year":"1993","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102259_b0295","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/00002030-200307250-00001","article-title":"A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi\u2019s sarcoma","volume":"17","author":"Portsmouth","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2021.102259_b0300","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2018.12.036","article-title":"Diagnosis and treatment of Kaposi\u2019s sarcoma: European consensus-based interdisciplinary guideline (EDF\/EADO\/EORTC)","volume":"114","author":"Lebbe","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0305","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/sj.jid.5701215","article-title":"Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi\u2019s sarcoma: a multicenter study","volume":"128","author":"Di Lorenzo","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2021.102259_b0310","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003256.pub2","article-title":"Treatment of severe or progressive Kaposi\u2019s sarcoma in HIV-infected adults","author":"Gbabe","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2021.102259_b0315","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.10634","article-title":"Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma","volume":"95","author":"Tulpule","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0320","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi\u2019s sarcoma","volume":"17","author":"Gill","year":"1999","journal-title":"J Clin Oncol"},{"issue":"10231","key":"10.1016\/j.ctrv.2021.102259_b0325","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(19)33222-2","article-title":"Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial","volume":"395","author":"Krown","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2021.102259_b0330","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for Symptomatic Kaposi\u2019s Sarcoma in People With and Without HIV Infection: A Phase I\/II Study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0335","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2000.18.7.1550","article-title":"Vinorelbine is an effective and safe drug for AIDS-related Kaposi\u2019s sarcoma: results of a phase II study","volume":"18","author":"Nasti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0340","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.2002.12.038","article-title":"Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi\u2019s sarcoma: an AIDS Clinical Trials Group clinical study","volume":"20","author":"Evans","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0345","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/ced.13302","article-title":"Ring a ring o\u2019roses, a patient with Kaposi\u2019s? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy","volume":"43","author":"Harris","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ctrv.2021.102259_b0350","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2011.39.6853","article-title":"Phase II study of bevacizumab in patients with HIV-associated Kaposi\u2019s sarcoma receiving antiretroviral therapy","volume":"30","author":"Uldrick","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0355","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/bjd.13897","article-title":"Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma","volume":"173","author":"Mourah","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2021.102259_b0360","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2012.48.6365","article-title":"Phase II trial of imatinib in AIDS-associated Kaposi\u2019s sarcoma: AIDS Malignancy Consortium Protocol 042","volume":"32","author":"Koon","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0365","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2021.102259_b0370","volume":"37","author":"Zer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0375","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/acr.2019.07.02","article-title":"Intimal sarcoma of the pulmonary artery, a diagnostic enigma","volume":"3","author":"Barmpas","year":"2019","journal-title":"AME Case Rep"},{"key":"10.1016\/j.ctrv.2021.102259_b0380","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10554-018-1489-8","article-title":"Imaging and Surgical Treatment of Primary Pulmonary Artery Sarcoma","volume":"35","author":"Wyler von Ballmoos","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.ctrv.2021.102259_b0385","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3348\/kjr.2018.19.4.792","article-title":"Pulmonary Artery Intimal Sarcoma versus Pulmonary Artery Thromboembolism: CT and Clinical Findings","volume":"19","author":"Kim","year":"2018","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.ctrv.2021.102259_b0390","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10554-019-01553-5","article-title":"Value of (18)F-FDG PET\/CT in differentiating malignancy of pulmonary artery from pulmonary thromboembolism: a cohort study and literature review","volume":"35","author":"Xi","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"issue":"18","key":"10.1016\/j.ctrv.2021.102259_b0395","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.4103\/0366-6999.189910","article-title":"Endovascular Catheter-guided Forceps Biopsy for the Diagnosis of Suspected Pulmonary Artery Sarcoma: A Preliminary Study of Eight Cases","volume":"129","author":"Xie","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ctrv.2021.102259_b0400","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091283","article-title":"Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets","volume":"11","author":"Roszik","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0405","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/PAS.0000000000000184","article-title":"Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas","volume":"38","author":"Neuville","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0410","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/ejcts\/ezs387","article-title":"Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma","volume":"43","author":"Mussot","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ctrv.2021.102259_b0415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jtcvs.2013.07.054","article-title":"Surgical treatment of primary pulmonary artery sarcoma","volume":"148","author":"Grazioli","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2021.102259_b0420","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.athoracsur.2008.08.018","article-title":"Management of primary pulmonary artery sarcomas","volume":"87","author":"Blackmon","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2021.102259_b0425","doi-asserted-by":"crossref","first-page":"7941432","DOI":"10.1155\/2017\/7941432","article-title":"Multimodal Approach of Pulmonary Artery Intimal Sarcoma: A Single-Institution Experience","volume":"2017","author":"Secondino","year":"2017","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2021.102259_b0430","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cncr.32508","article-title":"Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network","volume":"126","author":"Frezza","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0435","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1038\/s41467-018-03891-9","article-title":"Integrated genetic and epigenetic analysis of mixofibrosarcoma","volume":"9","author":"Ogura","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0440","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0445","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1245\/s10434-010-1341-4","article-title":"Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution","volume":"18","author":"Sanfilippo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0450","first-page":"1042","article-title":"Surgical margins do not affect prognosis in high grade myxofibrosarcoma","volume":"42","author":"Sambri","year":"2016","journal-title":"J Cancer Surg"},{"key":"10.1016\/j.ctrv.2021.102259_b0455","doi-asserted-by":"crossref","unstructured":"Fujiwara T, Stevenson J, Parry M, Tsuda Y, Tsoi K, Jeys L. What is an adequate margin for infiltrative soft - tissue sarcomas? Eur J Surg Oncol. doi:10.1016\/j.ejso.2019.10.005.","DOI":"10.1016\/j.ejso.2019.10.005"},{"key":"10.1016\/j.ctrv.2021.102259_b0460","article-title":"The role of surgical margin quality in myxofibrosarcoma and undifferentiated pleomorphic sarcoma","author":"Fujiwara","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0465","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2010.08.042","article-title":"Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma","volume":"82","author":"Haglund","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2021.102259_b0470","doi-asserted-by":"crossref","first-page":"8517371","DOI":"10.1155\/2019\/8517371","article-title":"High Recurrence Rate of Myxofibrosarcoma: The Effect of Radiotherapy Is Not Clear","volume":"2019","author":"Teurneau","year":"2019","journal-title":"Sarcoma"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102259_b0475","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13569-017-0082-6","article-title":"Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma","volume":"22","author":"Colia","year":"2017","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0480","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/curroncol28010078","article-title":"Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series","volume":"28","author":"Elkrief","year":"2021","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0485","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.4143\/crt.2017.529","article-title":"Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report","volume":"50","author":"Song","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0490","doi-asserted-by":"crossref","first-page":"E677","DOI":"10.3390\/cancers11050677","article-title":"MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma\/Myxofibrosarcoma","volume":"11","author":"Conley","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b0495","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000507334","article-title":"The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives","volume":"43","author":"Sambri","year":"2020","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ctrv.2021.102259_b0500","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/modpathol.2017.94","article-title":"Expanding molecular profiling of myxofibrosarcoma reveals potentially actionable targets","volume":"30","author":"Heitzer","year":"2017","journal-title":"Modern Pathol"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102259_b0505","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978\u20132001: An analysis of 26,758 cases","volume":"119","author":"Toro","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0510","series-title":"Bone and Soft Tissue Pathology","article-title":"Fibroblastic and Fibrohistiocytic Tumors","author":"Guillou","year":"2010"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0515","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1097\/PAS.0b013e3181ef70b6","article-title":"Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period","volume":"34","author":"Bahrami","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0520","first-page":"307","article-title":"Atlas of musculoskeletal tumors and tumors like lesions","author":"Picci","year":"2014","journal-title":"Cham"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0525","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/his.12282","article-title":"Fibrosarcoma: a review and update","volume":"64","author":"Folpe","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2021.102259_b0530","unstructured":"McFarlane-Parrot SC. Fibrosarcoma 2002. http:\/\/www.encyclopedia.com.last [accessed:10.12.2014]."},{"key":"10.1016\/j.ctrv.2021.102259_b0535","series-title":"Diagnostic pathology","article-title":"Soft tissue tumor","author":"Limberg","year":"2016"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0540","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/PAS.0000000000001194","article-title":"Novel NTRK3 Fusions in Fibrosarcomas of Adults","volume":"43","author":"Yamazaki","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0545","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s11999-011-2167-5","article-title":"Extremity soft tissue sarcoma resections","volume":"470","author":"King","year":"2012","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0550","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11523-013-0294-5","article-title":"Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin","volume":"9","author":"Bao","year":"2014","journal-title":"Target Oncol"},{"issue":"4 Suppl. 3","key":"10.1016\/j.ctrv.2021.102259_b0555","first-page":"289","article-title":"Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy","volume":"34","author":"Perisano","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0560","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1586\/era.12.180","article-title":"Fibroblastic tumors of intermediate malignancy in childhood","volume":"13","author":"Ferrari","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0565","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.siny.2012.05.003","article-title":"Neonatal soft tissue sarcomas","volume":"17","author":"Ferrari","year":"2012","journal-title":"Semin Fetal Neonatal Med"},{"issue":"22","key":"10.1016\/j.ctrv.2021.102259_b0570","first-page":"5046","article-title":"ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma","volume":"58","author":"Knezevich","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102259_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2015.12.028","article-title":"Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience","volume":"57","author":"Orbach","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b0580","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/modpathol.2017.12","article-title":"Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma","volume":"30","author":"Santiago","year":"2017","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b0585","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/1097-0142(19950915)76:6<1073::AID-CNCR2820760624>3.0.CO;2-L","article-title":"Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification\u2014an Intergroup Rhabdomyosarcoma Study","volume":"76","author":"Newton","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0590","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.aott.2019.08.008","article-title":"Unusual localization and aggressive progression of large infantile fibrosarcoma","volume":"53","author":"Burak Atalay","year":"2019","journal-title":"Acta Orthopaed Traumatol Turcica"},{"key":"10.1016\/j.ctrv.2021.102259_b0595","article-title":"The impact of local control in the treatment of children with advanced infantile and adult type fibrosarcoma: experience of the Cooperative Weichteilsarkom Studiengruppe (CWS)","author":"Sparber-Sauer","year":"2019","journal-title":"J Pediat Surg"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102259_b0600","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00383-013-3318-4","article-title":"Margin status and multimodal therapy in infantile fibrosarcoma","volume":"29","author":"Sulkowski","year":"2013","journal-title":"Pediatr Surg Int"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0605","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2009.21.9972","article-title":"Infantile fibrosarcoma: management based on the European experience","volume":"28","author":"Orbach","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0610","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumors harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase \u00bd study [published correction appears in Lancet Oncol. 2018 May;19(5):e229]","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0615","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03215511."},{"key":"10.1016\/j.ctrv.2021.102259_b0620","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02568267."},{"key":"10.1016\/j.ctrv.2021.102259_b0625","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02650401."},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0630","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pbc.25733","article-title":"Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma","volume":"63","author":"Yanagisawa","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102259_b0635","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26813","article-title":"Analysis of infantile fibrosarcoma reveals extensive T-cell responses within tumors: Implications for immunotherapy","volume":"65","author":"Zhu","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102259_b0640","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/JTO.0b013e3182653d64","article-title":"Malignant solitary fibrous tumors of the pleura: retrospective review of a multicenter series","volume":"7","author":"Lococo","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102259_b0645","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1308\/rcsann.2015.0023","article-title":"Doege-Potter Syndrome","volume":"97","author":"Ahluwalia","year":"2015","journal-title":"Ann R Coll Surg Engl"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0650","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/modpathol.2013.164","article-title":"Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics","volume":"27","author":"Doyle","year":"2014","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0655","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2214\/AJR.16.16662","article-title":"Metastatic Patterns of Solitary Fibrous Tumors: A Single-Institution Experience","volume":"208","author":"O\u2019Neill","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102259_b0660","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/modpathol.2012.83","article-title":"Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model","volume":"25","author":"Demicco","year":"2012","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0665","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/modpathol.2017.54","article-title":"Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model","volume":"30","author":"Demicco","year":"2017","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0670","first-page":"313","article-title":"Solitary, fibrous tumor: An evolving and unifying entity with unsettled issues","volume":"34","author":"Huang","year":"2019","journal-title":"Histol Histopathol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0675","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/107327480601300403","article-title":"Solitary fibrous tumor of the pleura","volume":"13","author":"Robinson","year":"2006","journal-title":"Cancer Control"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0680","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF02303499","article-title":"Hemangiopericytoma: a 20-year single-institution experience","volume":"5","author":"Spitz","year":"1998","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102259_b0685","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/cncr.10867","article-title":"Conventional hemangiopericytoma: modern analysis of outcome","volume":"95","author":"Espat","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0690","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/his.13703","article-title":"TERT promoter mutations in solitary fibrous tumor","volume":"73","author":"Demicco","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2021.102259_b0695","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdx250","article-title":"Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database","volume":"28","author":"Salas","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0700","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/cncr.10328","article-title":"Clinicopathologic correlates of solitary fibrous tumors","volume":"94","author":"Gold","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0705","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clinimag.2017.10.002","article-title":"Solitary fibrous tumor in the abdomen and pelvis: A case series with radiological findings and treatment recommendations","volume":"48","author":"Fernandez","year":"2018","journal-title":"Clin Imaging"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0710","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.ijrobp.2003.09.079","article-title":"Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma","volume":"58","author":"Ballo","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0715","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/1097-0142(19850801)56:3<475::AID-CNCR2820560311>3.0.CO;2-S","article-title":"Radiation therapy alone for sarcoma of soft tissue","volume":"56","author":"Tepper","year":"1985","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102259_b0720","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0725","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1440-1827.2007.02083.x","article-title":"Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy","volume":"57","author":"Kawamura","year":"2007","journal-title":"Pathol Int"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0730","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ejca.2013.03.017","article-title":"Response to chemotherapy of solitary fibrous tumor: a retrospective study","volume":"49","author":"Stacchiotti","year":"2013","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b0735","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/1078155218784760","article-title":"Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumor: A population-based analysis","volume":"25","author":"De Lemos","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ctrv.2021.102259_b0740","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1186\/s12885-015-1697-8","article-title":"Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group","volume":"15","author":"Khalifa","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0745","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","article-title":"Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumor: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Martin-Broto","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0750","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1470-2045(19)30826-5","article-title":"Pazopanib for treatment of typical solitary fibrous tumors: a multicentre, single-arm, phase 2 trial","volume":"21","author":"Martin-Broto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102259_b0755","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1093\/annonc\/mds143","article-title":"Sunitinib malate in solitary fibrous tumor (SFT)","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0760","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2018.10.024","article-title":"Activity of axitinib in progressive advanced solitary fibrous tumor: Results from an exploratory, investigator-driven phase 2 clinical study","volume":"106","author":"Stacchiotti","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2021.102259_b0765","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.11558","article-title":"Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study","volume":"39","author":"Stacchiotti","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.ctrv.2021.102259_b0770","first-page":"v683","article-title":"A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I\/II trial of sunitinib plus nivolumab in advanced soft tissue sarcomas: results of the phase II-soft-tissue sarcoma cohort","volume":"30","author":"Martin Broto","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0775","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1078-0432.CCR-10-2621","article-title":"Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors","volume":"17","author":"Quek","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0780","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(13)70049-4","article-title":"Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial","volume":"14","author":"Schwartz","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b0785","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3390\/jcm9061752","article-title":"Dermatofibrosarcoma Protuberans: Update on the Diagnosis and Treatment","volume":"9","author":"Hao","year":"2020","journal-title":"J Clin Med"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102259_b0790","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ejca.2015.06.108","article-title":"Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline","volume":"51","author":"Saiag","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0795","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ng0197-95","article-title":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma","volume":"15","author":"Simon","year":"1997","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102259_b0800","first-page":"3719","article-title":"The dermatofibrosarcoma protuberans-associated collagen type Ialpha1\/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB","volume":"59","author":"Shimizu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102259_b0805","article-title":"Multidisciplinary surgical treatment approach for dermatofibrosarcoma protuberans: an update","author":"Ava","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ctrv.2021.102259_b0810","doi-asserted-by":"crossref","first-page":"297","DOI":"10.11604\/pamj.2019.33.297.17692","article-title":"The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans","volume":"33","author":"Malan","year":"2019","journal-title":"Pan Afr Med J"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0815","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13014-019-1226-z","article-title":"Role of postoperative radiotherapy in dermatofibrosarcoma protuberans: a propensity score-matched analysis","volume":"14","author":"Du","year":"2019","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102259_b0820","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/jdv.13601","article-title":"The efficacy of adjuvant radiotherapy in dermatofibrosarcoma protuberans: a systemic review and meta-analysis","volume":"30","author":"Chen","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0825","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102259_b0830","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/1078-0432.CCR-09-3401","article-title":"Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients","volume":"16","author":"K\u00e9rob","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0835","first-page":"8288","article-title":"Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib","volume":"8","author":"Fu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.ctrv.2021.102259_b0840","unstructured":"J. Delyon R. Porcher M. Battistella N. Meyer H. Adamski F. Bertucci et al. A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans J Invest Dermatol 2020 S0022\u2013202X(20)32067-4 10.1016\/j.jid.2020.06.039."},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0845","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/PAS.0b013e31822b3687","article-title":"Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up","volume":"35","author":"Evans","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0850","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.anndiagpath.2017.04.001","article-title":"Low-grade fibromyxoid sarcoma: Clinical, morphologic and genetic features","volume":"28","author":"Mohamed","year":"2017","journal-title":"Ann Diagn Pathol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0855","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/PAS.0b013e318210c268","article-title":"MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma","volume":"35","author":"Doyle","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0860","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/256280","article-title":"Low-Grade Fibromyxoid Sarcoma: Incidence, Treatment Strategy of Metastases, and Clinical Significance of the FUS Gene","volume":"2013","author":"Maretty-Nielsen","year":"2013","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2021.102259_b0865","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21873\/invivo.11766","article-title":"Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy","volume":"34","author":"Chamberlain","year":"2020","journal-title":"Vivo"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0870","first-page":"48","article-title":"Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California","volume":"7","author":"Seto","year":"2019","journal-title":"Med Sci (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b0875","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00000478-200106000-00001","article-title":"Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor","volume":"25","author":"Antonescu","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0880","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1097\/PAS.0b013e3182562bf8","article-title":"MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement","volume":"36","author":"Doyle","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102259_b0885","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/PAS.0b013e3180321959","volume":"31","author":"Guillou","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0890","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/PAS.0000000000001423","article-title":"Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma","volume":"44","author":"Puls","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0895","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/PAS.0000000000001382","article-title":"Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma","volume":"44","author":"Kao","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b0900","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/00006123-200010000-00031","article-title":"Sclerosing epithelioid fibrosarcomas involving the neuraxis: report of three cases","volume":"47","author":"Bilsky","year":"2000","journal-title":"Neurosurgery"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102259_b0905","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12032-018-1192-6","article-title":"Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma","volume":"35","author":"Chew","year":"2018","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102259_b0910","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102259_b0915","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0920","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK","volume":"35","author":"Mari\u00f1o-Enr\u00edquez","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b0925","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/his.12910","article-title":"nflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study","volume":"69","author":"Yamamoto","year":"2016","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b0930","first-page":"E60","article-title":"Inflammatory myofibroblastic tumor","volume":"52","author":"Firat","year":"2009","journal-title":"Can J Surg"},{"issue":"18","key":"10.1016\/j.ctrv.2021.102259_b0935","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b0940","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-2600(18)30116-4","volume":"6","author":"Sch\u00f6ffski","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"28","key":"10.1016\/j.ctrv.2021.102259_b0945","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children\u2019s Oncology Group Study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102259_b0950","article-title":"The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis [published online ahead of print, 2020 Jun 25]","author":"Baldi","year":"2020","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102259_b0955","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/1759-7714.13520","article-title":"Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases [published online ahead of print, 2020 Jun 3]","volume":"11","author":"Si","year":"2020","journal-title":"Thorac Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102259_b0960","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.5858\/arpa.2017-0219-RA","article-title":"Myxoinflammatory Fibroblastic Sarcoma: Review and Update","volume":"141","author":"Lucas","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0965","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/RCT.0000000000000490","article-title":"Myxoinflammatory Fibroblastic Sarcoma: Clinical, Imaging, Management and Outcome in 29 Patients","volume":"41","author":"Kumar","year":"2017","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.ctrv.2021.102259_b0970","article-title":"Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases [published online ahead of print, 2020 Jun 8]","author":"Suster","year":"2020","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102259_b0975","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.5858\/arpa.2013-0549-RS","article-title":"Myxoinflammatory fibroblastic sarcoma: morphologic and genetic updates","volume":"138","author":"Ieremia","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b0980","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.otsr.2009.11.018","article-title":"Acral myxoinflammatory fibroblastic sarcoma","volume":"96","author":"Chahdi","year":"2010","journal-title":"Orthop Traumatol Surg Res"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b0985","first-page":"45","article-title":"Myxoinflammatory Fibroblastic Sarcoma Treated With Mohs Micrographic Surgery","volume":"1","author":"Huber","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.ctrv.2021.102259_b0990","doi-asserted-by":"crossref","first-page":"86.e1","DOI":"10.1053\/j.jfas.2009.07.028","article-title":"Myxoinflammatory Fibroblastic Sarcoma: A Case Report and Review of the Literature","volume":"49","author":"Monson","year":"2010","journal-title":"J Foot Ankle Surg"},{"issue":"24","key":"10.1016\/j.ctrv.2021.102259_b0995","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.25567","article-title":"Management of acral myxoinflammatory fibroblastic sarcoma","volume":"116","author":"Tejwani","year":"2010","journal-title":"Cancer"},{"issue":"1075","key":"10.1016\/j.ctrv.2021.102259_b1000","doi-asserted-by":"crossref","first-page":"20170039","DOI":"10.1259\/bjr.20170039","article-title":"Angiosarcoma: clinical and imaging features from head to toe","volume":"90","author":"Gaballah","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctrv.2021.102259_b1005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clinimag.2019.06.002","article-title":"Imaging findings in epithelioid hemangioendothelioma","volume":"58","author":"Epelboym","year":"2019","journal-title":"Clin Imaging"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b1010","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1148\/rg.264055129","article-title":"Imaging manifestations of Kaposi sarcoma","volume":"26","author":"Restrepo","year":"2006","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b1015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00256-014-1992-5","article-title":"An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI","volume":"44","author":"Kikuta","year":"2015","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ctrv.2021.102259_b1020","first-page":"1","article-title":"CT and MRI Findings of Soft Tissue Adult Fibrosarcoma in Extremities","volume":"2018","author":"Wang","year":"2018","journal-title":"Hindawi, Biomed Res Int"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102259_b1025","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1148\/rg.2016150191","article-title":"Pediatric Fibroblastic and Myofibroblastic Tumors: A Pictorial Review","volume":"36","author":"Sargar","year":"2016","journal-title":"Radiographics"},{"issue":"06","key":"10.1016\/j.ctrv.2021.102259_b1030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4172\/2161-069X.1000536","article-title":"Clinical analysis of CT and MRI Features of Solitary Fibrous Tumor of the Soft Tissues","volume":"07","author":"Feng","year":"2017","journal-title":"J Gastrointest Dig Syst"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b1035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jmu.2013.01.009","article-title":"Ultrasound Appearances of Dermatofibrosarcoma Protuberans","volume":"21","author":"Lee","year":"2013","journal-title":"J Med Ultrasound"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102259_b1040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12891-018-1976-z","article-title":"MRI findings of low-grade fibromyxoid sarcoma: a case report and literature review","volume":"19","author":"Yue","year":"2018","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102259_b1045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s11999-008-0205-8","article-title":"Sclerosing epithelioid fibrosarcoma: Case presentation and a systematic review","volume":"466","author":"Ossendorf","year":"2008","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b1050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rcl.2015.12.005","article-title":"Inflammatory Myofibroblastic Tumors: Current Update","volume":"54","author":"Surabhi","year":"2016","journal-title":"Radiol Clin North Am"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102259_b1055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00256-015-2286-2","article-title":"Myxoinflammatory fibroblastic sarcoma: spectrum of disease and imaging presentation","volume":"45","author":"Gaetke-Udager","year":"2016","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ctrv.2021.102259_b1060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-981-10-7230-7_16","article-title":"Pathological Features of Kaposi\u2019s Sarcoma-Associated Herpesvirus Infection","volume":"1045","author":"Katano","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ctrv.2021.102259_b1065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/path.4322","article-title":"A novel SERPINE1-FOSB fusion gene results in transcriptional upregulation of FOSB in pseudomyogenic haemangioendothelioma","volume":"232","author":"Walther","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b1070","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000001147","article-title":"Expanding the spectrum of genetic alterations in pseudomyogenic hemangioendothelioma with recurrent Novel ACTB-FOSB gene fusions","volume":"42","author":"Agaram","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b1075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41379-018-0175-7","article-title":"Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma","volume":"32","author":"Zhu","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2021.102259_b1080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.21873\/cgp.20134","article-title":"Fusion of the Genes WWTR1 and FOSB in Pseudomyogenic Hemangioendothelioma","volume":"16","author":"Panagopoulos","year":"2019","journal-title":"Cancer Genom Proteom"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102259_b1085","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.humpath.2008.04.016","article-title":"An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features","volume":"39","author":"Chen","year":"2008","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102259_b1090","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/modpathol.2014.165","article-title":"Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors","volume":"28","author":"Hornick","year":"2015","journal-title":"Mod Pathol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:29:04Z","timestamp":1759656544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":218,"alternative-id":["S0305737221001079"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102259","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS \u2013 GROUP). Part I","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102259"}}